Atea Pharmaceuticals Inc. AVIR
$4.30
▲ +2.98% 24H
About
Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapeutics to address serious viral infections. Its primary product candidate, bemnifosbuvir, a nucleotide NS5B inhibitor, targets COVID-19 caused by SARS-CoV-2 and its varian…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees55
TickerAVIR
Statistics
Market Cap$344.5M
Revenue (TTM)—
Net Income-$158.3M
Net Margin—
EPS$-1.94
P/E-2.27
P/S—
P/B1.49
EV/EBITDA-0.51
ROE-52.6%
Dividend Yield—
Price$4.30
Data: Twelve Data · Revenue = mcap / P/S